Janux Therapeutics Stock One Year Return
| JANX Stock | USD 46.39 1.61 3.35% |
Janux Therapeutics fundamentals help investors to digest information that contributes to Janux Therapeutics' financial success or failures. It also enables traders to predict the movement of Janux Stock. The fundamental analysis module provides a way to measure Janux Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Janux Therapeutics stock.
Janux |
Janux Therapeutics Company One Year Return Analysis
Janux Therapeutics' One Year Return is the annualized return generated from holding a security for exactly 12 months. The measure is considered to be good short-term measures of fund performance. In other words, it represents the capital appreciation of fund investments over the last year. However when the market is volatile such as in recent years, One Year Return measure can be misleading.
More About One Year Return | All Equity Analysis
One Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although One Year Fund Return indicator can give a sense of overall fund short-term potential, it is recommended to look at mid and long term return measure before selecting a particular fund or ETF. The great way to validate fund short-term performance is to compare it with other similar funds or ETFs for the same 12 months interval.
| Competition |
Based on the recorded statements, Janux Therapeutics has an One Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Janux One Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Janux Therapeutics' direct or indirect competition against its One Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Janux Therapeutics could also be used in its relative valuation, which is a method of valuing Janux Therapeutics by comparing valuation metrics of similar companies.Janux Therapeutics is currently under evaluation in one year return category among its peers.
Janux Fundamentals
| Return On Equity | -0.12 | ||||
| Return On Asset | -0.0993 | ||||
| Operating Margin | (81.64) % | ||||
| Current Valuation | 1.8 B | ||||
| Shares Outstanding | 52.48 M | ||||
| Shares Owned By Insiders | 7.74 % | ||||
| Shares Owned By Institutions | 94.58 % | ||||
| Number Of Shares Shorted | 4.19 M | ||||
| Price To Book | 3.71 X | ||||
| Price To Sales | 186.58 X | ||||
| Revenue | 8.08 M | ||||
| Gross Profit | (44.83 M) | ||||
| EBITDA | (71.02 M) | ||||
| Net Income | (58.29 M) | ||||
| Cash And Equivalents | 338.76 M | ||||
| Cash Per Share | 8.15 X | ||||
| Total Debt | 24.54 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 21.08 X | ||||
| Book Value Per Share | 12.54 X | ||||
| Cash Flow From Operations | (50.58 M) | ||||
| Short Ratio | 6.05 X | ||||
| Earnings Per Share | (1.17) X | ||||
| Price To Earnings To Growth | (0.98) X | ||||
| Target Price | 67.25 | ||||
| Number Of Employees | 76 | ||||
| Beta | 3.52 | ||||
| Market Capitalization | 2.43 B | ||||
| Total Asset | 380.41 M | ||||
| Retained Earnings | (168.76 M) | ||||
| Working Capital | 336.21 M | ||||
| Net Asset | 380.41 M |
About Janux Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Janux Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Janux Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Janux Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.